{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:34:46Z","timestamp":1768509286255,"version":"3.49.0"},"posted":{"date-parts":[[2023,11,29]]},"group-title":"Neuroscience","reference-count":70,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,11,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Prion diseases are invariably fatal neurodegenerative diseases of humans and other animals for which there are no treatment options. Previous work from our laboratory identified phenethyl piperidines as novel class of anti-prion compounds. While working to identify the molecular target(s) of these molecules, we unexpectedly discovered ten novel anti-prion compounds based on their known ability to bind to the sigma receptors, \u03c3\n                  <jats:sub>1<\/jats:sub>\n                  R and\n                  <jats:sub>2<\/jats:sub>\n                  R, which are currently being tested as therapeutic or diagnostic targets for cancer and neuropsychiatric disorders. Surprisingly, however, knockout of the respective genes encoding \u03c3\n                  <jats:sub>1<\/jats:sub>\n                  R and \u03c3\n                  <jats:sub>2<\/jats:sub>\n                  R (\n                  <jats:italic>Sigmar1<\/jats:italic>\n                  and\n                  <jats:italic>Tmem97<\/jats:italic>\n                  ), in prion infected N2a cells did not alter the anti-prion activity of these compounds, demonstrating that these receptors are not the direct targets responsible the anti-prion effects of their ligands. Further investigation of the most potent molecules established that they are efficacious against multiple prion strains and protect against downstream prion-mediated synaptotoxicity. While the precise details of the mechanism of action of these molecules remains to be determined, the present work forms the basis for further investigations of these compounds in pre-clinical studies. Given the therapeutic utility of several of the tested compounds, including rimcazole and haloperidol for neuropsychiatric conditions, (+)-pentazocine for neuropathic pain, and the ongoing clinical trials of SA 4503 and ANAVEX2-73 for ischemic stroke and Alzheimer\u2019s disease, respectively, this work has immediate implications for the treatment of human prion disease.\n                <\/jats:p>","DOI":"10.1101\/2023.11.28.569035","type":"posted-content","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T20:10:43Z","timestamp":1701288643000},"source":"Crossref","is-referenced-by-count":0,"title":["Sigma receptor ligands are potent anti-prion compounds that act independently of sigma receptor binding"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6029-511X","authenticated-orcid":false,"given":"Robert C. C.","family":"Mercer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nhat T. T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei C. Q.","family":"Houser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron B.","family":"Beeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023120100151128000_2023.11.28.569035v1.1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.23.13363"},{"key":"2023120100151128000_2023.11.28.569035v1.2","doi-asserted-by":"crossref","first-page":"e1006826","DOI":"10.1371\/journal.ppat.1006826","article-title":"A novel Gerstmann-Str\u00e4ussler- Scheinker disease mutation defines a precursor for amyloidogenic 8 kDa PrP fragments and reveals N-terminal structural changes shared by other GSS alleles","volume":"14","year":"2018","journal-title":"PLoS pathogens"},{"key":"2023120100151128000_2023.11.28.569035v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202133260704"},{"key":"2023120100151128000_2023.11.28.569035v1.4","doi-asserted-by":"crossref","unstructured":"Mercer, R. C. , McDonald, A. J. , Bove-Fenderson, E. , Fang, C. , Wu, B. , and Harris, D. A . (2018) Prion diseases. in The Molecular and Cellular Basis of Neurodegenerative Diseases, Elsevier. pp 23\u201356","DOI":"10.1016\/B978-0-12-811304-2.00002-X"},{"key":"2023120100151128000_2023.11.28.569035v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2021.08.011"},{"key":"2023120100151128000_2023.11.28.569035v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27923-z"},{"key":"2023120100151128000_2023.11.28.569035v1.7","doi-asserted-by":"crossref","unstructured":"Manka, S. W. , Wenborn, A. , Betts, J. , Joiner, S. , Saibil, H. R. , Collinge, J. , and Wadsworth, J. D . (2023) A structural basis for prion strain diversity. Nature Chemical Biology, 1-7","DOI":"10.1101\/2022.05.17.492259"},{"key":"2023120100151128000_2023.11.28.569035v1.8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010947"},{"key":"2023120100151128000_2023.11.28.569035v1.9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","article-title":"Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial","volume":"8","year":"2009","journal-title":"The Lancet Neurology"},{"key":"2023120100151128000_2023.11.28.569035v1.10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","article-title":"Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"13","year":"2014","journal-title":"The Lancet Neurology"},{"key":"2023120100151128000_2023.11.28.569035v1.11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1317164110"},{"key":"2023120100151128000_2023.11.28.569035v1.12","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01502-07"},{"key":"2023120100151128000_2023.11.28.569035v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2005.06.053"},{"key":"2023120100151128000_2023.11.28.569035v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2013.11.009"},{"key":"2023120100151128000_2023.11.28.569035v1.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009062107"},{"key":"2023120100151128000_2023.11.28.569035v1.16","doi-asserted-by":"crossref","unstructured":"Masone, A. , Zucchelli, C. , Caruso, E. , Lavigna, G. , Era\u00f1a, H. , Giachin, G. , Tapella, L. , Comerio, L. , Restelli, E. , and Raimondi, I . (2023) A tetracationic porphyrin with dual anti-prion activity. iScience","DOI":"10.1016\/j.isci.2023.107480"},{"key":"2023120100151128000_2023.11.28.569035v1.17","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nmeth1131","article-title":"Prion strain discrimination using luminescent conjugated polymers","volume":"4","year":"2007","journal-title":"Nature methods"},{"key":"2023120100151128000_2023.11.28.569035v1.18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.355958"},{"key":"2023120100151128000_2023.11.28.569035v1.19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.234393"},{"key":"2023120100151128000_2023.11.28.569035v1.20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.745612"},{"key":"2023120100151128000_2023.11.28.569035v1.21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.064949"},{"key":"2023120100151128000_2023.11.28.569035v1.22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005623"},{"key":"2023120100151128000_2023.11.28.569035v1.23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.coph.2018.12.005","article-title":"Identification of anti-prion drugs and targets using toxicity- based assays","volume":"44","year":"2019","journal-title":"Current opinion in pharmacology"},{"key":"2023120100151128000_2023.11.28.569035v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/nature11691"},{"key":"2023120100151128000_2023.11.28.569035v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(96)00161-X"},{"key":"2023120100151128000_2023.11.28.569035v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00208-3"},{"key":"2023120100151128000_2023.11.28.569035v1.27","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.bmcl.2007.12.056","article-title":"Tritium radiolabelling of PB28, a potent sigma-2 receptor ligand: pharmacokinetic and pharmacodynamic characterization","volume":"18","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"2023120100151128000_2023.11.28.569035v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(86)90640-5"},{"key":"2023120100151128000_2023.11.28.569035v1.29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.17.5618"},{"key":"2023120100151128000_2023.11.28.569035v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00201-4"},{"key":"2023120100151128000_2023.11.28.569035v1.31","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110379286"},{"key":"2023120100151128000_2023.11.28.569035v1.32","first-page":"284","article-title":"Evidence for sigma opioid receptor: binding of [3H] SKF-10047 to etorphine- inaccessible sites in guinea-pig brain","volume":"223","year":"1982","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"2023120100151128000_2023.11.28.569035v1.33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.22.8784"},{"key":"2023120100151128000_2023.11.28.569035v1.34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/npp.1994.5","article-title":"BMY 14802, a sigma receptor ligand for the treatment of schizophrenia","volume":"10","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"2023120100151128000_2023.11.28.569035v1.35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710054104"},{"key":"2023120100151128000_2023.11.28.569035v1.36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/crispr.2021.0113","article-title":"Inference of CRISPR edits from Sanger trace data","volume":"5","year":"2022","journal-title":"The CRISPR Journal"},{"key":"2023120100151128000_2023.11.28.569035v1.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2286-9"},{"key":"2023120100151128000_2023.11.28.569035v1.38","doi-asserted-by":"publisher","DOI":"10.1126\/science.abi4708"},{"key":"2023120100151128000_2023.11.28.569035v1.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2006.08.061"},{"key":"2023120100151128000_2023.11.28.569035v1.40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00441-021-03572-y","article-title":"Cell biology of prion strains in vivo and in vitro","volume":"392","year":"2023","journal-title":"Cell and Tissue Research"},{"key":"2023120100151128000_2023.11.28.569035v1.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2006.03889.x"},{"key":"2023120100151128000_2023.11.28.569035v1.42","doi-asserted-by":"publisher","DOI":"10.1046\/j.1472-8206.2002.00063.x"},{"key":"2023120100151128000_2023.11.28.569035v1.43","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfm157"},{"key":"2023120100151128000_2023.11.28.569035v1.44","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01563-07"},{"key":"2023120100151128000_2023.11.28.569035v1.45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007283"},{"key":"2023120100151128000_2023.11.28.569035v1.46","first-page":"1","article-title":"A novel and rapid method for obtaining high titre intact prion strains from mammalian brain","volume":"5","year":"2015","journal-title":"Scientific Reports"},{"key":"2023120100151128000_2023.11.28.569035v1.47","doi-asserted-by":"publisher","DOI":"10.1038\/nature17391"},{"key":"2023120100151128000_2023.11.28.569035v1.48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1705154114"},{"key":"2023120100151128000_2023.11.28.569035v1.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04175-x"},{"key":"2023120100151128000_2023.11.28.569035v1.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.07.006"},{"key":"2023120100151128000_2023.11.28.569035v1.51","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.50.30221"},{"key":"2023120100151128000_2023.11.28.569035v1.52","doi-asserted-by":"crossref","unstructured":"Mercer, R. C. , and Harris, D. A . (2022) Mechanisms of prion-induced toxicity. Cell and Tissue Research, 1\u201316","DOI":"10.1007\/s00441-022-03683-0"},{"key":"2023120100151128000_2023.11.28.569035v1.53","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5062-06.2007"},{"key":"2023120100151128000_2023.11.28.569035v1.54","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.216671"},{"key":"2023120100151128000_2023.11.28.569035v1.55","first-page":"1269","article-title":"The antidepressant-like effect induced by \u03c21-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test","volume":"298","year":"2001","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"2023120100151128000_2023.11.28.569035v1.56","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2008.192"},{"key":"2023120100151128000_2023.11.28.569035v1.57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2004.tb00001.x"},{"key":"2023120100151128000_2023.11.28.569035v1.58","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.6.885"},{"key":"2023120100151128000_2023.11.28.569035v1.59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.genhosppsych.2020.08.008","article-title":"Intravenous haloperidol: A systematic review of side effects and recommendations for clinical use","volume":"67","year":"2020","journal-title":"General Hospital Psychiatry"},{"key":"2023120100151128000_2023.11.28.569035v1.60","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.005835"},{"key":"2023120100151128000_2023.11.28.569035v1.61","first-page":"e12013","article-title":"A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer\u2019s disease therapy: analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study","volume":"6","year":"2020","journal-title":"Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions"},{"key":"2023120100151128000_2023.11.28.569035v1.62","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10224"},{"key":"2023120100151128000_2023.11.28.569035v1.63","doi-asserted-by":"publisher","DOI":"10.1038\/nbt748"},{"key":"2023120100151128000_2023.11.28.569035v1.64","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1021\/acs.jmedchem.9b00449","article-title":"Synthesis and Structure\u2013Affinity Relationships of Spirocyclic Benzopyrans with Exocyclic Amino Moiety","volume":"62","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"2023120100151128000_2023.11.28.569035v1.65","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0402"},{"key":"2023120100151128000_2023.11.28.569035v1.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.01.042"},{"key":"2023120100151128000_2023.11.28.569035v1.67","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.262790"},{"key":"2023120100151128000_2023.11.28.569035v1.68","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00213-009-1505-8","article-title":"The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism","volume":"204","year":"2009","journal-title":"Psychopharmacology"},{"key":"2023120100151128000_2023.11.28.569035v1.69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2009.07.001","article-title":"The pharmacology of sigma-1 receptors","volume":"124","year":"2009","journal-title":"Pharmacology & therapeutics"},{"key":"2023120100151128000_2023.11.28.569035v1.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbrainres.2003.12.019"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.11.28.569035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:35:26Z","timestamp":1768455326000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.11.28.569035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":70,"URL":"https:\/\/doi.org\/10.1101\/2023.11.28.569035","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1021\/acschemneuro.4c00095","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,11,29]]},"subtype":"preprint"}}